Compare $ALZN vs $SKYE | Chartloom

Compare

$ALZN vs $SKYE

Alzamend Neuro Inc · Skye Bioscience Inc

ALZN

Alzamend Neuro Inc

SKYE

Skye Bioscience Inc

Compare $ALZN vs $SKYE

Comparing Alzamend Neuro Inc and Skye Bioscience Inc

ALZNAlzamend Neuro Inc

SKYESkye Bioscience Inc

ALZNAlzamend Neuro Inc

Market cap

$6M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-29.5%

52W performance

-47.0%

FCF yield

-106.6%

SKYESkye Bioscience Inc

Market cap

$59M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-75.9%

52W performance

-87.7%

FCF yield

-65.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALZN

SKYE

Detailed metrics comparison

ALZN

Alzamend Neuro Inc

SKYE

Skye Bioscience Inc

Market Cap

ALZN$6M

SKYE$59M

Enterprise Value

ALZN$-1M

SKYE$51M

Price

ALZN$1.34

SKYE$1.69

P/E Ratio

ALZNN/A

SKYEN/A

P/S Ratio

ALZN0.00x

SKYE26.57x

EV/Sales

ALZN0.00x

SKYE0.00x

EV/EBITDA

ALZN0.00x

SKYE0.00x

P/B Ratio

ALZN1.14x

SKYE0.83x

P/FCF Ratio

ALZNN/A

SKYEN/A

EV/FCF

ALZN0.17x

SKYE-1.31x

PEG Ratio

ALZNN/A

SKYEN/A

Forward P/E (NTM)

ALZNN/A

SKYEN/A

Forward P/S (NTM)

ALZNN/A

SKYEN/A

Revenue (TTM)

ALZN$0

SKYE$0

Revenue Growth (YoY)

ALZNN/A

SKYEN/A

Forward Rev Growth

ALZN0.0%

SKYE307.4%

Gross Margin (TTM)

ALZN0.0%

SKYE39.3%

Operating Margin (TTM)

ALZN0.0%

SKYE0.0%

EBITDA Margin (TTM)

ALZN0.0%

SKYE0.0%

Net Margin (TTM)

ALZN0.0%

SKYE0.0%

FCF Margin (TTM)

ALZNN/A

SKYEN/A

Net Income (TTM)

ALZN$-9M

SKYE$-50M

FCF (TTM)

ALZN$-7M

SKYE$-39M

EPS (TTM)

ALZN-$2.03

SKYE-$10.18

ROE (TTM)

ALZN-27788.0%

SKYE-21727.0%

ROA (TTM)

ALZN-18419.0%

SKYE-20179.0%

ROIC (TTM)

ALZN-27788.0%

SKYE-21675.0%

Cash

ALZN$8M

SKYE$9M

Debt

ALZN$0

SKYE$143K

Net Cash/Debt

ALZN$8M

SKYE$8M

Current Ratio (TTM)

ALZN3.01x

SKYE0.95x

Quick Ratio (TTM)

ALZN2.77x

SKYE0.91x

Debt/Equity (TTM)

ALZN0.00x

SKYE0.03x

Debt/Assets (TTM)

ALZN0.0%

SKYE0.0%

Interest Coverage (TTM)

ALZNN/A

SKYEN/A

Net Debt/EBITDA (TTM)

ALZN0.00x

SKYE0.00x

Beta

ALZN0.43

SKYE3.13

52W Performance

ALZN-47.0%

SKYE-87.7%

YTD Performance

ALZN-29.5%

SKYE-75.9%

% from 52W High

ALZN-50.0%

SKYE-88.0%

% from 52W Low

ALZN59.5%

SKYE12.7%

Asset Turnover (TTM)

ALZN0.00x

SKYE1.93x

FCF Yield (TTM)

ALZN-106.6%

SKYE-65.4%

Earnings Yield (TTM)

ALZN-141.7%

SKYE-85.0%

Dividend Yield (TTM)

ALZNN/A

SKYEN/A

Rule of 40

ALZN0.0

SKYE0.0

EV/GP/RG

ALZNN/A

SKYEN/A

Ticker research

View ALZN research View SKYE research

Metric	ALZN Alzamend Neuro Inc	SKYE Skye Bioscience Inc
Market & Valuation
Market Cap	$6M	$59M
Enterprise Value	$-1M	$51M
Price	$1.34	$1.69
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	26.57x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.14x	0.83x
P/FCF Ratio	N/A	N/A
EV/FCF	0.17x	-1.31x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	307.4%
Profitability
Gross Margin (TTM)	0.0%	39.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-9M	$-50M
FCF (TTM)	$-7M	$-39M
EPS (TTM)	-$2.03	-$10.18
ROE (TTM)	-27788.0%	-21727.0%
ROA (TTM)	-18419.0%	-20179.0%
ROIC (TTM)	-27788.0%	-21675.0%
Financial Health
Cash	$8M	$9M
Debt	$0	$143K
Net Cash/Debt	$8M	$8M
Current Ratio (TTM)	3.01x	0.95x
Quick Ratio (TTM)	2.77x	0.91x
Debt/Equity (TTM)	0.00x	0.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.43	3.13
52W Performance	-47.0%	-87.7%
YTD Performance	-29.5%	-75.9%
% from 52W High	-50.0%	-88.0%
% from 52W Low	59.5%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.93x
FCF Yield (TTM)	-106.6%	-65.4%
Earnings Yield (TTM)	-141.7%	-85.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ALZN research	View SKYE research

Valuation

P/S Ratio

ALZN

0.00x

SKYE

26.57x

EV/FCF

SKYE

-1.31x

ALZN

0.17x

Growth & revenue

Forward Revenue Growth

SKYE

307.4%

ALZN

0.0%

Profitability & performance

Gross Margin

SKYE

39.3%

ALZN

0.0%

ROE

SKYE

-21727.0%

ALZN

-27788.0%

FCF Yield %

SKYE

-65.4%

ALZN

-106.6%

52-Week Performance

ALZN

-47.0%

SKYE

-87.7%

Detailed metrics comparison

ALZN

Alzamend Neuro Inc

SKYE

Skye Bioscience Inc

Market Cap

ALZN$6M

SKYE$59M

Enterprise Value

ALZN$-1M

SKYE$51M

Price

ALZN$1.34

SKYE$1.69

P/E Ratio

ALZNN/A

SKYEN/A

P/S Ratio

ALZN0.00x

SKYE26.57x

EV/Sales

ALZN0.00x

SKYE0.00x

EV/EBITDA

ALZN0.00x

SKYE0.00x

P/B Ratio

ALZN1.14x

SKYE0.83x

P/FCF Ratio

ALZNN/A

SKYEN/A

EV/FCF

ALZN0.17x

SKYE-1.31x

PEG Ratio

ALZNN/A

SKYEN/A

Forward P/E (NTM)

ALZNN/A

SKYEN/A

Forward P/S (NTM)

ALZNN/A

SKYEN/A

Revenue (TTM)

ALZN$0

SKYE$0

Revenue Growth (YoY)

ALZNN/A

SKYEN/A

Forward Rev Growth

ALZN0.0%

SKYE307.4%

Gross Margin (TTM)

ALZN0.0%

SKYE39.3%

Operating Margin (TTM)

ALZN0.0%

SKYE0.0%

EBITDA Margin (TTM)

ALZN0.0%

SKYE0.0%

Net Margin (TTM)

ALZN0.0%

SKYE0.0%

FCF Margin (TTM)

ALZNN/A

SKYEN/A

Net Income (TTM)

ALZN$-9M

SKYE$-50M

FCF (TTM)

ALZN$-7M

SKYE$-39M

EPS (TTM)

ALZN-$2.03

SKYE-$10.18

ROE (TTM)

ALZN-27788.0%

SKYE-21727.0%

ROA (TTM)

ALZN-18419.0%

SKYE-20179.0%

ROIC (TTM)

ALZN-27788.0%

SKYE-21675.0%

Cash

ALZN$8M

SKYE$9M

Debt

ALZN$0

SKYE$143K

Net Cash/Debt

ALZN$8M

SKYE$8M

Current Ratio (TTM)

ALZN3.01x

SKYE0.95x

Quick Ratio (TTM)

ALZN2.77x

SKYE0.91x

Debt/Equity (TTM)

ALZN0.00x

SKYE0.03x

Debt/Assets (TTM)

ALZN0.0%

SKYE0.0%

Interest Coverage (TTM)

ALZNN/A

SKYEN/A

Net Debt/EBITDA (TTM)

ALZN0.00x

SKYE0.00x

Beta

ALZN0.43

SKYE3.13

52W Performance

ALZN-47.0%

SKYE-87.7%

YTD Performance

ALZN-29.5%

SKYE-75.9%

% from 52W High

ALZN-50.0%

SKYE-88.0%

% from 52W Low

ALZN59.5%

SKYE12.7%

Asset Turnover (TTM)

ALZN0.00x

SKYE1.93x

FCF Yield (TTM)

ALZN-106.6%

SKYE-65.4%

Earnings Yield (TTM)

ALZN-141.7%

SKYE-85.0%

Dividend Yield (TTM)

ALZNN/A

SKYEN/A

Rule of 40

ALZN0.0

SKYE0.0

EV/GP/RG

ALZNN/A

SKYEN/A

Ticker research

View ALZN research View SKYE research

Metric	ALZN Alzamend Neuro Inc	SKYE Skye Bioscience Inc
Market & Valuation
Market Cap	$6M	$59M
Enterprise Value	$-1M	$51M
Price	$1.34	$1.69
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	26.57x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.14x	0.83x
P/FCF Ratio	N/A	N/A
EV/FCF	0.17x	-1.31x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	307.4%
Profitability
Gross Margin (TTM)	0.0%	39.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-9M	$-50M
FCF (TTM)	$-7M	$-39M
EPS (TTM)	-$2.03	-$10.18
ROE (TTM)	-27788.0%	-21727.0%
ROA (TTM)	-18419.0%	-20179.0%
ROIC (TTM)	-27788.0%	-21675.0%
Financial Health
Cash	$8M	$9M
Debt	$0	$143K
Net Cash/Debt	$8M	$8M
Current Ratio (TTM)	3.01x	0.95x
Quick Ratio (TTM)	2.77x	0.91x
Debt/Equity (TTM)	0.00x	0.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.43	3.13
52W Performance	-47.0%	-87.7%
YTD Performance	-29.5%	-75.9%
% from 52W High	-50.0%	-88.0%
% from 52W Low	59.5%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.93x
FCF Yield (TTM)	-106.6%	-65.4%
Earnings Yield (TTM)	-141.7%	-85.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ALZN research	View SKYE research